TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple ...

NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3

Related Keywords

Colorado ,United States ,United Kingdom ,West Palm Beach ,Florida ,Lawrence Steinman ,Enrique Alvarez ,National Multiple Sclerosis Society ,Tg Therapeutics Inc ,Research In Multiple Sclerosis ,Cms Center ,Drug Administration ,European Commission ,Zimmermann Professor Of Neurology Neurological Sciences ,Missouri Baptist Medical Center ,Pediatrics At Stanford University ,University Of Colorado ,Linkedin ,Sclerosis International Federation ,Healthcare Products Regulatory Agency ,Globe Newswire Tg Therapeutics Inc ,Exchange Commission ,Americas Committee For Treatment ,Nasdaq ,Americas Committee ,Multiple Sclerosis ,Presentation Title ,Pseudoexacerbation Paradox ,High Efficacy Therapy ,Poster Session ,Poster Number ,Barry Singer ,Baptist Medical Center ,Expanded Disability Status Scale ,Zimmermann Professor ,Neurological Sciences ,Hepatitisb Virus ,Multifocal Leukoencephalopathy ,Infants Born ,Common Adverse Reactions ,Formerly Twitter ,Private Securities Litigation Reform Act ,Annual Report ,Accessed October ,Multiple Sclerosis International Federation ,Region ,